Additionally, ex vivo images in Figure 6(D) from harvested tumors also confirmed obviously higher fluorescence in the HER2-LsbMDDs group than those from the LsbMDDs and DNS-LsbMDDs groups, which was further evidence of the higher tumor targeting efficiency of the HER2-LsbMDDs. The gene discussed is ERBB2; the disease is neoplasm.